127 related articles for article (PubMed ID: 18565964)
21. Tiotropium versus salmeterol in COPD.
Lloret-Linares C; Bergmann JF
N Engl J Med; 2011 Jun; 364(26):2552-3; author reply 2553-4. PubMed ID: 21714656
[No Abstract] [Full Text] [Related]
22. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
Baloira Villar A; Vilariño Pombo C
Arch Bronconeumol; 2005 Mar; 41(3):130-4. PubMed ID: 15766465
[TBL] [Abstract][Full Text] [Related]
23. Tiotropium versus salmeterol in COPD.
Schembri S
N Engl J Med; 2011 Jun; 364(26):2553; author reply 2553-4. PubMed ID: 21714655
[No Abstract] [Full Text] [Related]
24. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
Cazzola M; Andò F; Santus P; Ruggeri P; Di Marco F; Sanduzzi A; D'Amato M
Pulm Pharmacol Ther; 2007; 20(5):556-61. PubMed ID: 16914336
[TBL] [Abstract][Full Text] [Related]
25. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
Rodrigo GJ; Neffen H
Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635
[TBL] [Abstract][Full Text] [Related]
26. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
Hanania NA; Crater GD; Morris AN; Emmett AH; O'Dell DM; Niewoehner DE
Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533
[TBL] [Abstract][Full Text] [Related]
27. Chronic obstructive pulmonary disease megatrials: taking the results into office practice.
Stoloff SW
Am J Med Sci; 2011 Aug; 342(2):160-7. PubMed ID: 21512392
[TBL] [Abstract][Full Text] [Related]
28. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD.
Perng DW; Tao CW; Su KC; Tsai CC; Liu LY; Lee YC
Eur Respir J; 2009 Apr; 33(4):778-84. PubMed ID: 19129278
[TBL] [Abstract][Full Text] [Related]
29. [Debates surrounding COPD].
Tillie-Leblond I; Housset B
Rev Mal Respir; 2010 Feb; 27(2):106-7. PubMed ID: 20206057
[No Abstract] [Full Text] [Related]
30. Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD.
Andò F; Ruggeri P; Girbino G; Cazzola M
Respir Med; 2008 Jun; 102(6):815-8. PubMed ID: 18343646
[TBL] [Abstract][Full Text] [Related]
31. Stepping down therapy in COPD.
Reilly JJ
N Engl J Med; 2014 Oct; 371(14):1340-1. PubMed ID: 25196116
[No Abstract] [Full Text] [Related]
32. Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.
Dransfield MT; Bailey WC
Expert Opin Pharmacother; 2004 Aug; 5(8):1815-26. PubMed ID: 15264996
[TBL] [Abstract][Full Text] [Related]
33. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis.
Liu Y; Shi H; Sun X; Zhang D; Zhang Y; Yang K; Mi L; Li M
Eur J Intern Med; 2014 Jun; 25(5):491-5. PubMed ID: 24816076
[TBL] [Abstract][Full Text] [Related]
34. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
Dalal AA; Candrilli SD; Davis KL
Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
[TBL] [Abstract][Full Text] [Related]
35. Tiotropium versus salmeterol in COPD.
Restrick L; Stern M; Baxter N
N Engl J Med; 2011 Jun; 364(26):2552; author reply 2553-4. PubMed ID: 21714657
[No Abstract] [Full Text] [Related]
36. Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?
Tennant RC; Erin EM; Barnes PJ; Hansel TT
Curr Opin Pharmacol; 2003 Jun; 3(3):270-6. PubMed ID: 12810191
[TBL] [Abstract][Full Text] [Related]
37. The functional impact of adding salmeterol and tiotropium in patients with stable COPD.
Cazzola M; Centanni S; Santus P; Verga M; Mondoni M; di Marco F; Matera MG
Respir Med; 2004 Dec; 98(12):1214-21. PubMed ID: 15588043
[TBL] [Abstract][Full Text] [Related]
38. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
Rabe KF; Timmer W; Sagkriotis A; Viel K
Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
[TBL] [Abstract][Full Text] [Related]
39. Tiotropium versus salmeterol in COPD.
Oba Y
N Engl J Med; 2011 Jun; 364(26):2553; author reply 2553-4. PubMed ID: 21714654
[No Abstract] [Full Text] [Related]
40. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
Singh D; Brooks J; Hagan G; Cahn A; O'Connor BJ
Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
